Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Genetic differentiation and diversity of the Bolivian endemic titi monkeys, Plecturocebus modestus and Plecturocebus olallae.

Barreta Pinto J, Martinez J, Bernal Y, Sánchez R, Wallace R.

Primates. 2019 Sep 10. doi: 10.1007/s10329-019-00750-z. [Epub ahead of print]

PMID:
31506896
2.

[Cannabis and the teenager's brain].

Cortés ME, Bernal Y, Orellana R.

Rev Med Chil. 2019 Apr;147(4):533-534. doi: 10.4067/S0034-98872019000400533. Spanish. No abstract available.

3.

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ.

Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.

PMID:
31262783
4.

A Simple and Improved Predictor of Insulin Resistance Extracted From the Oral Glucose Tolerance Test: The I0*G60.

Contreras PH, Salgado AM, Bernal YA, Vigil P.

J Endocr Soc. 2019 Apr 10;3(6):1154-1166. doi: 10.1210/js.2018-00342. eCollection 2019 Jun 1.

5.

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ.

JCI Insight. 2019 Apr 2;5. pii: 122627. doi: 10.1172/jci.insight.122627.

6.

Terminal Complement Activation in Preeclampsia.

Burwick RM, Velásquez JA, Valencia CM, Gutiérrez-Marín J, Edna-Estrada F, Silva JL, Trujillo-Otálvaro J, Vargas-Rodríguez J, Bernal Y, Quintero A, Rincón M, Tolosa JE.

Obstet Gynecol. 2018 Dec;132(6):1477-1485. doi: 10.1097/AOG.0000000000002980.

PMID:
30399106
7.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

8.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

9.

[Andropause and vulnerability in health: when do we start to educate men and health professionals?].

Cortés ME, Bernal YA, Vigil P.

Rev Med Chil. 2016 Apr;144(4):541-3. doi: 10.4067/S0034-98872016000400023. Spanish. No abstract available.

10.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

11.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

12.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

13.

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M.

Mol Ther. 2010 Apr;18(4):666-8. doi: 10.1038/mt.2010.31. No abstract available.

14.

Semipreparative chiral supercritical fluid chromatography in the fractionation of lansoprazole and two related antiulcer drugs enantiomers.

Toribio L, del Nozal MJ, Bernal YL, Alonso C, Jiménez JJ.

J Sep Sci. 2008 May;31(8):1307-13. doi: 10.1002/jssc.200700457.

PMID:
18383242
15.

[Immunocytochemical and molecular studies with primary cultures of molar tissue].

Bernal YA, Díaz LE, Acosta J, Crane C, Carrasco-Rodríguez S, Bermúdez AJ, Sánchez-Gómez M.

Biomedica. 2006 Dec;26(4):509-16. Spanish.

PMID:
17315477

Supplemental Content

Loading ...
Support Center